EU/3/13/1151: Orphan designation for the treatment of malignant thymoma



On 17 July 2013, orphan designation (EU/3/13/1151) was granted by the European Commission to Topotarget A/S, Denmark, for belinostat for the treatment of malignant thymoma.

The sponsorship was transferred to Onxeo DK Filial af Onxeo S.A., Frankrig, Denmark, in June 2015.

Key facts

Active substance
Intended use
Treatment of malignant thymoma
Orphan designation status
EU designation number
Date of designation
Onxeo DK, Filial af Onxeo S.A., Frankrig
c/o Symbion
Fruebjergvej 3
2100 Copenhagen Ø
Tel. +45 3917 9494
Fax +45 3917 9492

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating